Filana Therapeutics (FLNA) Non-Current Assets (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Non-Current Assets of $20.2 million for Q2 2026, down 1.86% year-over-year from $20.6 million in Q2 2025, and down 1.09% quarter-over-quarter from $20.4 million in Q1 2026.
Filana Therapeutics (FLNA) Non-Current Assets (2010 - 2026) Analysis & Trends
Filana Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $20.2 million for Q2 2026.
- In Q2 2026, Non-Current Assets fell 1.86% year-over-year to $20.2 million; the TTM figure through Jun 2026 stood at $82.1 million (down 1.79% YoY), while the FY2025 annual figure was $20.6 million, down 1.69% from the prior year.
- Non-Current Assets for Q2 2026 stood at $20.2 million, down from $20.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $24.0 million in Q3 2022, with the low at $20.2 million in Q2 2026.
- The 5-year median for Non-Current Assets is $21.6 million (2024), against an average of $21.8 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 7643.31% in 2022, then declined 6.95% in 2023.
- Filana Therapeutics' Non-Current Assets stood at $23.6 million in 2022, then declined by 6.68% to $22.0 million in 2023, then declined by 4.67% to $21.0 million in 2024, then dropped by 1.69% to $20.6 million in 2025, then dropped by 2.26% to $20.2 million in 2026.
- Business Quant data shows FLNA's Non-Current Assets at $20.2 million in Q2 2026, $20.4 million in Q1 2026, and $20.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Filana Therapeutics | 46.00 Mn | 46.00 Mn | - | 20.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.18 Mn |
| Mar 31, 2026 | 20.40 Mn |
| Dec 31, 2025 | 20.65 Mn |
| Sep 30, 2025 | 20.82 Mn |
| Jun 30, 2025 | 20.56 Mn |
| Mar 31, 2025 | 20.78 Mn |
| Dec 31, 2024 | 21.00 Mn |
| Sep 30, 2024 | 21.20 Mn |
| Jun 30, 2024 | 21.45 Mn |
| Mar 31, 2024 | 21.72 Mn |
| Dec 31, 2023 | 22.03 Mn |
| Sep 30, 2023 | 22.35 Mn |
| Jun 30, 2023 | 22.72 Mn |
| Mar 31, 2023 | 23.11 Mn |
| Dec 31, 2022 | 23.61 Mn |
| Sep 30, 2022 | 24.01 Mn |
| Jun 30, 2022 | 23.18 Mn |
| Mar 31, 2022 | 21.99 Mn |
| Dec 31, 2021 | 22.30 Mn |
| Sep 30, 2021 | 22.33 Mn |